Browse
Browse
Home
People
Organizations
Research
Events
Capability Map
Elizabeth Alva
Assistant Professor
Close
E-mail
ealva@uab.edu
Links
Provider Directory
Visualizations
Co-investigator Network
Elizabeth Alva
Assistant Professor
Positions
Assistant Professor (P)
,
Pediatric - Hematology-Oncology
,
Pediatrics
Research
Background
Contact
Research
Principal Investigator On
ARST1921, A Safety, Pharmacokinetic and Efficacy Study of y-Secretase Inhibitor, Nirogacestat (PF03084014:IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
MCC 18613 Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
Multi-Institutional Retrospective Review of Infantile Sarcomas with Internal Tandem Duplication of BCOR
awarded by
CHILDREN'S HOSPITAL MEDICAL CENTER (CINCINNATI)
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
NIH National Clinical Trials Network (NCTN) Grant (2U10CA180886) Successor to NIH National Clinical Trials Network (NCTN Grant (U10CA180886)
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
NMTRC014: NMTT- Neuroblastoma Maintenance Therapy Trial Using Difluoromethylornithine (DFMO)
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
PEDS-PLAN – Pediatric Precision Laboratory Advanced Neuroblastoma Therapy A Study Using Molecular Guided Therapy with Induction Chemotherapy followed by a Randomized Controlled Trial of standard immunotherapy with or without DFMO followed by DFMO maintenance for Subjects with Newly Diagnosed High-Risk Neuroblastoma
awarded by
CHARLOTTE-MECKLENBURG HOSPITAL AUTHORITY - DBA ATRIUM HEALTH
Phase 1-11 Study of MEK 162 for Children with Progressive or Recurrent Cancer and A Phase 11 Study of Children with Low- Grade Gliomas and Other Ras/ RAF/MAP Pathway Activated Tumors
awarded by
CHILDREN'S HOSPITAL LA
Private Grant
awarded by
UNITED THERAPEUTICS CORPORATION
Investigator On
A Combination Therapy Trial using an Adaptive Platform Design for Children and Young Adults with Diffuse Midline Gliomas (DMGs) including Diffuse Intrinsic Pontine Gliomas (DIPGs) at Initial Diagnosis, Post-Radiation Therapy and at Time of Progression
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
A Phase 3 Randomized Trial for Newly Diagnosed High Risk B-precursor Acute Lymphoblastic Leukemia (ALL) Testing Clofarabine (IND# 73789, NSC # 606869) in the Very High Risk Stratum
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
A Phase I Trial Evaluating the Combination of Trametinib and Everolimus in Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas - 12797sc
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
A Randomized, Blinded, Pilot Trial of Neoadjuvant Checkpoint Inhibition followed by Adjuvant Checkpoint Inhibition in Children and Young Adults with Recurrent or Progressive High Grade Gliomac-UFRA-317
awarded by
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
AALL1331: Risk-Stratified Randomized Phase III Testing of Blinatumomab (IND#100135, NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AAML 1031 - Bayer
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ACTION Trial- Adoptive Cellular Therapy Following Dose-Intensified Temozolomide in Newly-Diagnosed Pediatric High-Grade Gliomas (Phase I)
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
ADVL 1515: A Phase 1 Study of LY2606368, A CHK 1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1615: A phase 1 Study of Pevonedistat (MLN4924), A Cullin Ligase Inhibitor, In Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refactory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL 1711: A Phase 1/2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1412, A Phase 1/2 Study of Nivolumab in Children Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1416: A Phase 1 Study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid Tumors, Including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1515: A Phase 1 Study of LY2606368, a CHK1/2 Inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1721: A Non-Randomized, Open Label, Multi-Center, Phase 1/11 Study of P13K Inhibitor Copanlisib in Pediatric Patients with Relapsed/Refactory Solid Tumors or Lymphoma
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
ADVL1722: A Phase 2, Multicenter, Open- Label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects with Relapsed/Refractory
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
AHOD1331 A Randomized Phase III Study of Brentuximab Vedotin (IND#117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
APEC1621SC - PEDIATRIC MATCH PCR - COG FOUNDATION
awarded by
CHILDREN'S ONCOLOGY GROUP
An Open-Label, Multi-Center Phase 1/2 study of Surufatinib in Combination with Gemcitabine in Pediatric Patients with Recurrent or Refractory Solid Tumors COG ADVL2121
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
BIQSFP-COG AALL1131 11XS189 Per Case Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
COG PCR - Per Case Reimbursement NIH National Clinical Trials Network (NCTN) Grant (U10CA180886) Successor to NIH COG Chair Grant (U10CA098543)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase II Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
CTSU: Phase ll Supplemental Payments (N02-CM-62212)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Cookies for Kids' Cancer Phase 1 Supplemental
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Headstart IV Clinical Study Rider
awarded by
NATIONWIDE CHILDREN'S
Institutional Support NIH Pediatric Early Phase Clinical Trials Network (PEP-CTN) Grant (UM1CA228823) Successor To NIH Phase I Grant (2UM1CA097452)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
LCH-IV: International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis
awarded by
St. Jude Children's Research Hospital
MCC 18613, Phase II Study of nab-Paclitaxel in Combination with Gemcitabine for Treatment of Recurrent/Refractory Sarcoma in Teenagers and Young Adults
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 19487 A Phase Ib/II Study to Evaluate the Safety, Feasibility and Efficacy of Nivolumab or Nivolumab in Combination with 5-Azacytidine in Patients with Recurrent, Resectable Osteosarcoma
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20320 Blood Based Biomarkers for Minimal Residual Disease Detection in Pediatric Sarcomas
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
MCC 20339 Evolutionary Inspired Therapy for Newly Diagnosed, Metastatic, Fusion Positive Rhabdomyosarcoma
awarded by
H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE
NIH COG Phase I Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Neuroanatomical, Cognitive, and Family Aspects to Recovery from a Brain Tumor
awarded by
NATIONWIDE CHILDREN'S
PEPN2111- A Phase 1/2 Trial of CBL0137 (NSC# 825802, IND# 155843) in Patients with Relapsed or Refractory Solid Tumors including CNS Tumors and Lymphoma,
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Pediatric Early Phase Clinical Trial Network Grant (UM1CA228823) (PEPCTN)
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement (PCR)- NIH National Clinical Trails Network (NCTN) Grant (U10CA180886) -PHI/COG
awarded by
PUBLIC HEALTH INSTITUTE (PHI)
Per Case Reimbursement COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement and Patient Studies Funds: NIH COG Phase 1 Grant
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Per Case Reimbursement: COG NCORP Research Base
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Palbociclib (Ibrance) in Combination with Irinotecan and Temozolomide in Pediatric Patients with Recurrent or Refractory Solid Tumors
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Phase I Study of MEK162 for Children with Progressive or Recurrent Cancer and a Phase II Study of Children with Low-Grade Gliomas and Other Ras/Raf/MAP Pathway Activated Tumors
awarded by
Childrens Hospital Los Angeles
Private Grant
awarded by
UNITED THERAPEUTICS CORPORATION
Private Grant
awarded by
Bayer AG
Private Grant
awarded by
NOVARTIS PHARMACEUTICALS CORPORATION
Private Grant
awarded by
ONCOCEUTICS INC
Private Grant
awarded by
SPRINGWORKS THERAPEUTICS ^
Private Grant
awarded by
EISAI, INC.
Project EveryChild APEC14B1
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Project Everychild APEC14B1
awarded by
CHILDREN'S ONCOLOGY GROUP
St. Baldricks Fdn Supplemental Reimbursement
awarded by
CHILDREN'S HOSPITAL (PHILADELPHIA)
Background
Education And Training
Denver Children's Hospital, Internship
Denver Children's Hospital, Residency
UAB Hospital, Postdoctoral Fellowship
Doctor of Medicine,
Medical College of Georgia
2008
Contact
Full Name
Elizabeth
Alva